SCIENCE@home

A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism

V. Lage-Rupprecht,Bruce Schultz,Justus Dick,Marcin Namysl,A. Zaliani,S. Gebel,O. Pless,Jeanette Reinshagen,B. Ellinger,Christian Ebeling,Alexander Esser,M. Jacobs,Carsten Claussen,M. Hofmann-Apitius

Published 2022 in Patterns

ABSTRACT

Summary The high number of failed pre-clinical and clinical studies for compounds targeting Alzheimer disease (AD) has demonstrated that there is a need to reassess existing strategies. Here, we pursue a holistic, mechanism-centric drug repurposing approach combining computational analytics and experimental screening data. Based on this integrative workflow, we identified 77 druggable modifiers of tau phosphorylation (pTau). One of the upstream modulators of pTau, HDAC6, was screened with 5,632 drugs in a tau-specific assay, resulting in the identification of 20 repurposing candidates. Four compounds and their known targets were found to have a link to AD-specific genes. Our approach can be applied to a variety of AD-associated pathophysiological mechanisms to identify more repurposing candidates.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-87 of 87 references · Page 1 of 1

CITED BY

Showing 1-15 of 15 citing papers · Page 1 of 1